Novavax’s stock was as low as $121 a share in mid-May of this year. The turbulence was caused by the perception that the pharmaceutical company had missed its opportunity to get its Covid-19 …
https://investorplace.com/2021/09/nvax-stock-is-a-buy-ahead-of-potential-eu-and-u-s-approvals/

